An immunohistochemical study of thioredoxin domain-containing 5 expression in gastric adenocarcinoma

Wu,Zhiming; Zhang,Lin; Li,Nan; Sha,Lina; Zhang,Kunpeng

doi:10.3892/ol.2014.2832

An immunohistochemical study of thioredoxin domain-containing 5 expression in gastric adenocarcinoma

Authors:
- Zhiming Wu
- Lin Zhang
- Nan Li
- Lina Sha
- Kunpeng Zhang
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, The 309 Hospital of People's Liberation Army, Beijing 100091, P.R. China
Published online on: December 29, 2014 https://doi.org/10.3892/ol.2014.2832
Pages: 1154-1158

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thioredoxin domain‑containing 5 (TXNDC5) is overexpressed in a number of human carcinomas. However, the involvement of TXNDC5 in gastric adenocarcinoma remains unclear. In the present study, the immunohistochemical expression and clinicopathological significance of TXNDC5 in gastric adenocarcinoma was investigated. The immunohistochemical expression of TXNDC5 was detected in 54 gastric adenocarcinoma specimens, and the correlation between TXNDC5 and the clinicopathological features was investigated. Of the 54 gastric adenocarcinoma specimens, 30 samples (55.6%) exhibited high TXNDC5 expression. In the adenocarcinoma specimens exhibiting high TXNDC5 expression, the proportion of poorly‑differentiated adenocarcinomas was significantly higher than that in specimens exhibiting low TXNDC5 expression (P<0.05). Lymph node metastasis and the depth of tumor invasion in the specimens exhibiting high TXNDC5 expression were significantly higher than that in specimens exhibiting low TXNDC5 expression (P<0.05). The results of a survival analysis revealed that the prognosis of patients exhibiting high TXNDC5 expression was significantly poorer than that of patients exhibiting low TXNDC5 expression (P<0.05). Therefore, the expression of TXNDC5 may correlate with the differentiation, invasion and metastasis of gastric adenocarcinoma. Thus, TXNDC5 may be a tumor‑enhancing gene that is involved in gastric cancer.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol. 12:354–362. 2006.PubMed/NCBI
3	Correa P: Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 52:6735–6740. 1992.PubMed/NCBI
4	González CA, Sala N and Capellá G: Genetic susceptibility and gastric cancer risk. Int J Cancer. 100:249–260. 2002. View Article : Google Scholar : PubMed/NCBI
5	Xue FB, Xu YY, Wan Y, et al: Association of H. pylori infection with gastric carcinoma: a Meta analysis. World J Gastroenterol. 7:801–804. 2001.
6	Zhang L, Hou YH, Wu K, et al: Proteomic analysis reveals molecular biological details in varioliform gastritis without Helicobacter pylori infection. World J Gastroenterol. 16:3664–3673. 2010. View Article : Google Scholar : PubMed/NCBI
7	Sullivan DC, Huminiecki L, Moore JW, et al: EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem. 278:47079–47088. 2003. View Article : Google Scholar : PubMed/NCBI
8	Chang X, Xu B, Wang L, et al: Investigating a pathogenic role for TXNDC5 in tumors. Int J Oncol. 43:1871–1884. 2013.PubMed/NCBI
9	Vincent EE, Elder DJ, Phillips L, et al: Overexpression of the TXNDC5 protein in non-small cell lung carcinoma. Anticancer Res. 31:1577–1582. 2011.PubMed/NCBI
10	Sobin LH and Wittekind C: TNM classification of malignant tumours. International Union Against Cancer. 5th edition. Wiley-Liss; New York, NY: pp. 54–58. 1997
11	Kase S, Osaki M, Honjo S, et al: Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch. 442:129–135. 2003.PubMed/NCBI
12	Nozoe T, Ezaki T, Kabashima A, Baba H and Maehara Y: Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg. 189:110–115. 2005. View Article : Google Scholar : PubMed/NCBI
13	Gallina F and Benedetti-Valentini F: Varioliform gastritis associated with gastric ulcer simulating a neoplasm. Riv Gastroenterol. 15:85–94. 1963.(In Italian). PubMed/NCBI
14	Vandenborre KM, Ghillebert GL, Rutgeerts LJ, et al: Hypertrophic lymphocytic gastritis with a gastric carcinoma. Eur J Gastroenterol Hepatol. 10:797–801. 1998. View Article : Google Scholar : PubMed/NCBI
15	Mosnier JF, Flejou JF, Amouyal G, et al: Hypertrophic gastropathy with gastric adenocarcinoma: Menetrier’s disease and lymphocytic gastritis? Gut. 32:1565–1567. 1991. View Article : Google Scholar : PubMed/NCBI
16	Zhang L, Hou Y, Li N, et al: The influence of TXNDC5 gene on gastric cancer cell. J Cancer Res Clin Oncol. 136:1497–1505. 2010. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Ma Y, Lü B, et al: Differential expression of mimecan and thioredoxin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study. Exp Biol Med (Maywood). 232:1152–1159. 2007. View Article : Google Scholar
18	Nissom PM, Lo SL, Lo JC, et al: Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma. FEBS Lett. 580:2216–2226. 2006. View Article : Google Scholar : PubMed/NCBI
19	Claudio JO, Masih-Khan E, Tang H, et al: A molecular compendium of genes expressed in multiple myeloma. Blood. 100:2175–2186. 2002. View Article : Google Scholar : PubMed/NCBI
20	Wei Q, Li M, Fu X, et al: Global analysis of differentially expressed genes in androgen-independent prostate cancer. Prostate Cancer Prostatic Dis. 10:167–174. 2007. View Article : Google Scholar : PubMed/NCBI